About the Company
We do not have any company description for TScan Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago. These figures are ...
TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should ...
TScan Therapeutics, Inc. (TCRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
TScan Therapeutics Reports Third Quarter 2024 Financial Results and ...
Contacts Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 hsavelle@tscan.com Maghan Meyers Argot Partners 212-600-1902 TScan@argotpartners.com ...
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent ...
Plans to continue to build ImmunoBank with additional IND filings throughout 2024. Long-term duration data for multiplexed therapy anticipated in 2025. About TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue ... - Nasdaq
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of ...
If you want to know who really controls TScan Therapeutics, Inc. (NASDAQ:TCRX), then you'll have to look at the makeup of its share registry. With 52% stake, institutions possess the maximum ...
TScan Therapeutics Reports Q2 2025 Financial Results
Tscan Therapeutics, Inc. ( ($TCRX) ) has released its Q2 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to ...
TCRX - TScan Therapeutics Inc Valuation | Morningstar
Review the current valuation for TScan Therapeutics Inc (TCRX:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
TCRX - TScan Therapeutics Inc Sustainability | Morningstar
Review TScan Therapeutics Inc (TCRX:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.
Similar Companies
Loading the latest forecasts...